对晚年失眠的行为和药理疗法:一个随机对照试验
C M Morin1, C Colecchi, J Stone
1Université Laval, Ecole de Psychologie, Sainte-Foy, Quebec, Canada. cmorin@psy.ulaval.ca
JAMA
|March 23, 1999
概括
认知行为疗法,单独或与药物结合,有效地治疗老年人的失眠. 与单独服用药物相比,行为方法随着时间的推移提供了持续的睡眠改善.
科学领域:
- 老年学是一门学科.
- 睡眠医学 睡眠医学
- 临床心理学 临床心理学
背景情况:
- 失眠是老年人常见的问题,影响他们的生活质量.
- 目前的治疗方法,如行为和药理疗法,都有优缺点.
- 之前没有任何研究直接比较这些治疗方法,单独和组合,用于老年人群的失眠.
研究的目的:
- 评估认知行为疗法 (CBT) 和药物治疗的有效性,单独和联合,对于老年人的失眠.
- 将这些干预与安慰剂对照组进行比较.
主要方法:
- 一个随机的,安慰剂对照试验进行了8周,随访时间为3,12和24个月.
- 78名患有慢性原发性失眠症的成年人 (平均年龄65岁) 参加了这项研究.
- 干预包括CBT,特马泽帕姆 (药物治疗),CBT和特马泽帕姆,或安慰剂.
主要成果:
- 所有的活性疗法在短期内都超过了安慰剂.
- 结合CBT和药物治疗的方法显示,比单独治疗更有改善睡眠的趋势.
- 认知行为疗法,无论是单独的还是联合的,被参与者和临床医生评为更有效和更令人满意的,随访时持续增长.
结论:
- 行为和药物治疗都能为晚年失眠提供短期缓解.
- 与单独的药物治疗相比,行为治疗表明睡眠改善的长期维持优越.
更多相关视频
05:59High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
Published on: October 20, 2023
04:59Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
相关概念视频
Blind Procedures
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
CNS Depressants: Barbiturates and Benzodiazepines
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
